TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$2.71 USD
-0.21 (-7.24%)
Updated Apr 29, 2024 03:57 PM ET
After-Market: $2.71 0.00 (0.00%) 4:50 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TFFP 2.71 -0.21(-7.24%)
Will TFFP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TFFP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TFFP
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates
TFFP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
Other News for TFFP
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
TFF Pharmaceuticals Signals Advancements in Investor Update
TFF Pharmaceuticals files to sell 147,500 shares of common stock for holders
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
TFF Pharmaceuticals announces data from TFF TAC Phase 2 trial